ONE MAN CAN AND WILL FIND A WAY,WHY NOT BE THAT MAN...
Chief Business Officer
Hans Preusting works as full time independent consultant. One of his main activities is to support Treeway with their business development activities.
Hans Preusting holds a PhD in Biochemistry from the university of Groningen, the Netherlands (1992) and a MBA degree from Rotterdam School of Management (2011). He has over 20 years of experience in the Life Science sector and has a track record in business development, product development and manufacturing using fermentation and cell culture techniques.
Prior to starting his own consultancy, he worked for several biotech and pharma companies in the Netherlands such uniQure, Solvay Pharmaceuticals (now Abbott), DSM Biologics and Gist-brocades (now DSM). Hans Preusting holds two patents and has published over 20 scientific articles.
Ronald van der Geest
Chief Development Officer
Ronald is Treeway’s CDO since 2013. He holds broad drug development experience. He led various development programs and supervised project leaders for a broad range of disease indications in the small molecule and biologics arena. As an example, he led the development of Prezista™ for Tibotec/Johnson&Johnson and more recently of Glybera™ for uniQure, the 1st approved gene therapy product in the EU.
He has been an advisor for many companies and life science institutes and has been involved in the management of various start-ups. Ronald holds strategic knowledge in the areas of translational development, orphan drugs, individualized and biomarker-based development.
He co-founded 3D-PharmXchange in 2010 and worked for various companies before, with focus on leadership and project management. He is a PhD-level clinical pharmacologist and drug delivery expert by training (Leiden University, UC San Francisco).
Inez de Greef
Chief Executive Officer
Inez de Greef is Treeway’s CEO since 2013.
In 2010, Inez de Greef founded 3D-PharmXchange, a consultancy firm providing integrated and immediate drug development and project management solutions to biotech and pharma companies. Prior to that, she was subsequently Director Clinical Development and COO of Kinesis Pharma. She also has worked several years on clinical and clinical pharmacology projects in several therapeutic areas, e.g. CNS-related diseases.At Tibotec-Virco, she was clinical pharmacology lead for the successfully approved HIV protease inhibitor Prezistra and follow-up compounds. At Leiden Advanced Experts on PK and PD (LAP&P) she was responsible for modeling & simulation projects and project management.Inez has a training in Medical Biology from the University of Amsterdam, the Netherlands, and obtained her PhD at the department of Pharmacology of the LACDR, Leiden University, with her thesis P-glycoprotein mediated transport across the blood-brain barrier.
Robbert Jan Stuit
Chief Financial Officer
Diagnosed in May 2011 with ALS. Managing director of an investment company and entrepreneur in real estate and technology.
He has vast experience in building companies in every stage of the life cycle.
Also co-founder of project MinE, the largest genetic study in ALS.
Robbert Jan holds a master degree in International Business Administration (Master Finance & Investment in Rotterdam and International Marketing in Stellenbosch).
A serial entrepreneur within the maritime & oil industry. He has introduced new business models in the largest port of Europe, for which he was awarded by the port of Rotterdam and in 2013 his company received the gold “gazelle” for fastest growing company in Holland.
Bernard has been confronted in June 2010 with adversity being diagnosed with ALS and since then has initiated the world-largest genetic research project for ALS, called project MinE and founded Treeway.